Key Highlights

• Shares of Soleno Therapeutics (SLNO) jumped more than 30% during premarket hours Monday following acquisition news
• Neurocrine Biosciences (NBIX) is nearing a deal to purchase Soleno in a transaction valued at $2.5B or higher
• The proposed acquisition could price SLNO shares in the low-to-mid $50 range
• According to the Financial Times, an agreement may be reached as early as Monday, April 6
• Shares of Neurocrine declined 0.4% premarket following the report

Soleno Therapeutics has experienced a challenging start to 2026 — posting losses of approximately 14% year to date — but Monday morning brought a dramatic reversal.

Soleno Therapeutics, Inc., SLNO

According to a Financial Times report, Neurocrine Biosciences has entered late-stage negotiations to acquire the rare disease-focused biotech company in a transaction exceeding $2.5 billion. News of the potential deal propelled SLNO shares more than 30% higher in premarket activity.

The proposed acquisition would place Soleno’s valuation in the low-to-mid $50s per share range. Negotiations are progressing at a rapid pace, with the FT indicating an announcement could come as soon as Monday.

Soleno’s primary commercial product is Vykat XR, which the company brought to market last year for treating hyperphagia — a medical condition associated with Prader-Willi syndrome. This condition triggers relentless, overwhelming hunger that can result in severe health complications such as gastric rupture, aspiration risks, morbid obesity, and heart disease.

Prader-Willi syndrome represents a rare genetic disorder with an incidence rate of approximately one case per 15,000 births. Vykat XR became the first FDA-approved therapeutic specifically targeting the insatiable appetite symptoms characteristic of this syndrome.

Industry analysts have projected Vykat XR could achieve peak yearly revenues reaching $2.3 billion — a commercial opportunity that has evidently attracted Neurocrine’s strategic interest.

Neurocrine’s Strategic Expansion Into Rare Diseases

Neurocrine currently maintains a market capitalization of approximately $13.21 billion. The company’s existing product lineup features Ingrezza, which addresses tardive dyskinesia and chorea associated with Huntington’s disease, alongside additional commercialized therapies and developmental pipeline assets.

Acquiring Vykat XR would establish Neurocrine’s presence in the rare disease and orphan drug sector, where companies typically benefit from premium pricing dynamics and reduced competitive pressure.

Neurocrine’s shares fell 0.4% in premarket activity Monday. Such modest declines are common when acquisition news breaks, as investors account for the premium the acquiring company must pay.

Understanding SLNO’s Recent Performance

Despite Monday’s dramatic surge, SLNO had posted year-to-date losses of roughly 14% in 2026 prior to this week’s news. The stock had underperformed despite analyst enthusiasm regarding Vykat XR’s revenue potential.

According to TipRanks, SLNO carries a Strong Buy rating based on assessments from 11 analysts. The consensus price target stands at $101.09, with the most bullish forecast reaching $125.

At the reported acquisition price in the low-to-mid $50s per share, the deal would fall considerably short of analyst price targets — although it would still represent a significant premium compared to SLNO’s recent trading levels.

The Financial Times report referenced individuals with knowledge of the negotiations, emphasizing that discussions are advancing smoothly and accelerating toward a potential finalization.

Key takeaways

• ADA is up 6% in the last 24 hours, making it the best performer among the top 20 cryptocurrencies by market cap.
• The coin could rally towards the $0.2772 resistance level if the rally persists.

Cardano (ADA) is building on recent gains, trading above $0.25 as of Monday after posting a modest recovery last week. A combination of stronger on-chain signals and improving derivatives data suggests the uptrend could continue. Technical indicators also point to growing momentum, reinforcing the case for a near-term rally.

On-chain and derivatives data lean bullish for Cardano

Data from Santiment’s Social Dominance metric supports a constructive outlook. This indicator tracks the proportion of ADA-related discussions across the broader crypto landscape. It has edged higher to 0.206% on Monday, signaling increased market attention and improving sentiment among investors.

On the derivatives front, CoinGlass shows Cardano’s long-to-short ratio at 1.01. A reading above 1 indicates that more traders are positioning for upside, reflecting a bullish bias in the market.

Meanwhile, Cardano’s funding rates turned positive on Thursday and have continued to climb, reaching 0.0076 on Monday. Positive funding rates suggest that long-position holders are paying shorts, a sign of strong demand. Historically, similar shifts from negative to positive funding, followed by rising rates, have coincided with upward price movements for ADA.

Cardano Price Forecast: ADA could extend gains towards $0.2772

The ADA/USD 4-hour chart is bearish and efficient as Cardano is trading above $0.25 on Monday. The near-term bias is mildly bullish as the price extends its recovery, nearing the key resistance at the 50-day EMA at $0.27. A breakout suggests an upward move. 

Currently, the momentum indicators have switched bullish. The Relative Strength Index (RSI) on the 4-hour chart at 67 leans bullish, signalling an impulsive buying pressure. 

The Moving Average Convergence Divergence (MACD) indicator has turned back above the signal line just under the zero mark, hinting at fading downside pressure.

If the market undergoes a correction, ADA would likely retest the first major support at $0.24. Breaking this support level would expose the $0.22 swing low where buyers previously emerged. 

However, if the rally persists, ADA could surge towards the $0.2772 resistance, coinciding with its 50-day EMA. A daily break above this level could see ADA surge towards the $0.2991 resistance level. 

Algorand price surged more than 50% over the past week, climbing to $0.126 on Monday and emerging as the top-performing cryptocurrency on the weekly timeframe.

According to data from crypto.news, Algorand (ALGO) rallied to an 11-week high of $0.126 on April 6, bringing its market cap near the $1.1 billion mark.

This rally followed a citation by Google Quantum AI in a research paper focused on the threats major blockchains face from quantum computing. The paper made several mentions of Algorand for its post-quantum security and advanced Falcon signature technology.

The token also gained significant traction after Revolut rolled out native ALGO staking, opening access for its 70 million-plus users to participate directly through the app.

There are three reasons why this rally could continue.

First, Algorand has confirmed a breakout from a multi-month falling wedge pattern on the daily chart. A falling wedge is formed by two descending and converging trendlines, and a breakout is often a precursor to sustained rallies. As such, the token could continue its climb to as high as $0.20, which aligns with the 50% Fibonacci retracement level. 

The forecast is supported by bullish technical indicators. Notably, the Aroon Up at 85.71% lies significantly above the Aroon Down, while the Chaikin Money Flow index showed a positive reading of 0.17, a sign that investors have been pouring capital into the asset.

Second, demand from its derivatives traders has been strong this week. 

Data from CoinGlass shows that open interest in its futures market has increased from $30 million to $75 million within a single week. Adding to this, the long/short ratio has moved above 1, suggesting that most traders are leaning bullish. This means that market sentiment is heavily skewed toward further price appreciation as participants bet on higher targets.

Third, the weighted funding rate for the token has turned negative. With the sudden surge in Algorand price, this environment creates the perfect conditions for a potential short squeeze.

A short squeeze would force sellers to cover their positions, providing the necessary momentum to propel the token rally toward the $2 target.

Executive Summary

• Constellation Brands delivers Q4 FY2026 financial results on April 8
• Consensus forecasts point to earnings per share between $1.71 and $1.74 with revenue around $1.87–$1.9 billion
• Options market anticipates a ±5.6% price movement following the release — significantly above the 2.89% historical quarterly average
• Beer segment revenue anticipated to remain steady at $1.71 billion year-over-year; Wine & Spirits revenue expected to decline 57.6%
• Wall Street consensus leans Moderate Buy with a $169.00 average target price, suggesting approximately 11.77% potential upside

Constellations Brands prepares to unveil its fourth quarter Fiscal 2026 financial performance on April 8, drawing significant attention from the investment community.

Constellation Brands, Inc., STZ

Wall Street forecasts are converging around earnings per share of $1.71 to $1.74, although UBS analyst Peter Grom takes a more conservative stance with a $1.59 projection — noticeably beneath the Street consensus. Revenue expectations range from $1.87 to $1.9 billion, representing an approximate 12–13% decline compared to the corresponding quarter in the previous fiscal year.

The anticipated revenue contraction stems predominantly from the Wine and Spirits division, where analysts project a dramatic 57.6% year-over-year decrease to approximately $194.97 million. This steep decline reflects Constellation’s divestiture of a substantial portion of that business segment, creating a challenging year-over-year comparison. Wine and Spirits operating income is forecast at a mere $2.39 million, a sharp contrast to the $99.70 million generated in the same period last year.

Meanwhile, the beer portfolio — featuring flagship brands Modelo and Pacifico — demonstrates resilience. Beer segment net sales are projected at $1.71 billion, essentially unchanged from the prior year period. Beer operating income expectations stand at $573.63 million, representing a modest decline from the $623.80 million recorded in last year’s fourth quarter.

Derivatives Market Signals Elevated Volatility Expectations

The options market is incorporating a ±5.6% price movement following the earnings announcement — substantially exceeding the stock’s 2.89% average post-earnings fluctuation across the previous four quarters. This elevated implied volatility indicates considerable market uncertainty surrounding the upcoming results.

Grom from UBS recently elevated his price objective to $176 from $168 while maintaining a Buy recommendation. He cautioned that investor expectations have climbed heading into the release, noting that STZ shares don’t consistently rally even following positive results. His analysis suggests any post-earnings weakness would likely prove temporary.

Evercore ISI analyst Robert Ottenstein takes a more optimistic view on the forthcoming numbers. His EPS model of $1.73 exceeds consensus estimates, and he anticipates beer sales will surpass Street projections. Ottenstein cited encouraging distributor commentary and strengthening beer volume trends as catalysts supporting his bullish outlook.

Premium Beer Portfolio Drives Narrative

Modelo continues ranking among the top-performing beer brands across the U.S. marketplace, with that momentum serving as the primary driver behind STZ’s positive year-to-date performance.

Ottenstein recognized potential margin headwinds from cost pressures but characterized the overall demand environment as solid. Grom reinforced this perspective, highlighting favorable category momentum and consistent market share expansion.

STZ maintains a Moderate Buy rating consensus across Wall Street — with nine Buy recommendations, five Hold ratings, and one Sell rating issued over the trailing three months. The consensus price target registers at $169.00.

During the past month, STZ delivered a +2.7% return, outperforming the S&P 500 composite’s -4.2% decline. The equity currently maintains a Zacks Rank #3 (Hold).

The Q4 financial results announcement is scheduled for April 8.

Prediction markets rapidly repriced the odds of US escalation in the Iran conflict, offering a real-time signal of geopolitical risk for traders.

Odds on platforms such as Polymarket and Kalshi shifted in real time as President Donald Trump paired new threats with signals of possible negotiations on Sunday, while Bitcoin (BTC) rose more than 3.5% on Monday.

Crypto prediction markets are no longer a sideshow during periods of geopolitical tension, with professional desks increasingly using them to gauge macro risk, according to Sygnum Bank chief investment officer Fabian Dori.  

“Prediction markets price discrete, named outcomes with real capital behind them,” Dori told Cointelegraph. “For crypto in particular, where so much price action is driven by specific binary events, regulatory decisions, geopolitical developments [and] protocol upgrades, that is a categorically different signal.”

Related: Brandt says Bitcoin yet to bottom, Polymarket sees hope: Trade Secrets

Throughout the Iran conflict escalation, prediction market odds on de-escalation shifted before mainstream financial media coverage caught up and “had direct correlation” with Bitcoin price, Dori added.

Prediction markets enter macro playbooks

On some professional desks, prediction markets are now used as a real-time event monitor during fast-moving geopolitical situations, alongside funding rates, options surfaces and flows, Dori said.

ARK Invest integrating Kalshi’s prediction market data into its investment process shows how event odds are migrating into mainstream institutional workflows.

In a regulated environment, prediction markets function as a context layer, informing how teams frame risk scenarios rather than serving as direct buy-or-sell signals. 

Related: Prediction markets are testing legal limits in strict Asian markets

“The goal is to decide what to do before the event happens,” he said, arguing that markets that continuously update a capital-weighted probability of war, sanctions or ceasefire are a natural fit for that discipline.

Institutional money and growing scrutiny

The flows are now large enough that institutional investors can no longer dismiss the signal as retail noise. In March, the number of prediction market transactions reached about 191 million, up 2,838% year-on-year, with monthly notional volume rising to roughly $23.9 billion. 

At the same time, traditional exchange operators are moving in. Intercontinental Exchange, the parent of the New York Stock Exchange, completed a new $600 million investment in Polymarket on March 27, deepening its conviction in prediction markets.

“This is no longer a niche product,” Dori said, adding that the real question for professional investors is no longer whether to watch Iran-linked markets at all, but “how to integrate them in a way that adds genuine analytical value rather than simply adding a new source of noise.”

The boom is also drawing tougher questions about fairness and integrity. Six Polymarket traders netted around $1 million betting on the timing of US strikes on Iran in late February, sparking insider trading concerns.

The platform also pulled a market on a missing US pilot on Saturday after backlash over over related wagers.

Magazine: Bitcoin’s ‘biggest bull catalyst’ would be Saylor’s liquidation — Santiment founder